1. Ferlay J, Shin B, Bray F, et al. Globocan 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10[internet]. Lyon, France. In: International Agency for Research on Cancer; 2010. [http://www.eurosafeimaging.org/wp/wpcontent/uploads/2015/05/Global-CancerStatistics.pdf]
2. Lowe K, Chia V, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013;130:107- 14. [https://pubmed.ncbi.nlm.nih.gov/23558050/]
3. American Cancer Society,2007. Cancer Facts and Figures. [ www.cancer.org.Links ]
4. Ferlay J, Shin B, Bray F, et al. Globocan 2008 v 2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [internet]. Lyon, France. In: International Agency for Research on Cancer; 2010 [ http://www.eurosafeimaging.org/wp/wp-content/uploads/2015/05/Global-Cancer-Statistics.pdf]
5. Vang R, Shih I, Kurman R. Ovarian lowgrade and high-grade serous carcinoma:Pathogenesis, clinic pathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009,16:267-82. [ https://www.remedypublications.com/open-access/mucinous-differentiation-in-a-high-gradeserous-epithelial-ovarian-carcinoma-7871.pdf]